U.S. flag

An official website of the United States government

CADTH Canadian Drug Expert Committee Final Recommendation: Ticagrelor: (Brilinta — AstraZeneca Canada Inc.): Indication: Secondary Prevention of Atherothrombotic Events [Internet].

CADTH Canadian Drug Expert Committee Final Recommendation: Ticagrelor: (Brilinta — AstraZeneca Canada Inc.): Indication: Secondary Prevention of Atherothrombotic Events [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016 Aug.

Table of contents


Supplemental Content

Search details

See more...

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
External link. Please review our privacy policy.